   Investors in Trellis Bioscience's Novel Human Antibody TherapeuticsTrellis is privately held and has raised $30 million from two rounds of venture funding. Investors include Series B lead investor Novartis Venture Fund, Morgenthaler Ventures, Easton Hunt Capital Partners, Sagamore BioVentures and Pac-Link BioVentures. Trellis Bioscience, Inc.
2-B Corporate Drive South San Francisco, CA 94080 tel 650.616.1100 Directions to Trellis Bioscience The CompanyAbout Trellis BioscienceTrellis Bioscience, Inc. discovers and develops novel human antibody therapeutics as treatments for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of four monoclonal antibodies in early stage development. PartnershipsTrellis has an antibody discovery partnership with PDL BioPharma and seeks additional partnerships with select pharmaceutical companies. Pilot programs with multiple other partners are completed or ongoing. Interested parties are invited to contact Trellis Business Development. |
